v3.26.1
Intangible Assets (Details)
3 Months Ended 12 Months Ended
Dec. 01, 2023
USD ($)
Mar. 05, 2023
USD ($)
Mar. 05, 2023
EUR (€)
Dec. 15, 2022
EUR (€)
Sep. 12, 2022
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Intangible Assets [Line Items]              
Purchase amount   $ 179,821          
Non Exclusive License Agreement [Member]              
Intangible Assets [Line Items]              
Purchase amount           $ 179,821 $ 179,821
Term fee   56,325 € 50,000        
Signing the agreement   (112,650) 100,000        
Payment of license   $ 1,126,500 € 1,000,000        
Royalty percentage   2.00% 2.00%        
Various Generic Drugs [Member]              
Intangible Assets [Line Items]              
Purchase amount           736,983  
Four Generic Drugs (Encore) [Member]              
Intangible Assets [Line Items]              
Purchase amount         $ 1,308,270    
Needleless Syringe License [Member]              
Intangible Assets [Line Items]              
Purchase amount $ 26,060            
Royalty fees           26,060 26,060
Patents [Member]              
Intangible Assets [Line Items]              
Purchase amount           48,420  
Patent cost           48,420 48,420
Licensing Agreements [Member]              
Intangible Assets [Line Items]              
Purchase amount           736,983 736,983
Licensing Agreements [Member] | Four Generic Drugs (Encore) [Member]              
Intangible Assets [Line Items]              
Purchase amount           1,308,270 1,308,270
Licensing Agreements [Member] | Needleless Syringe License [Member]              
Intangible Assets [Line Items]              
Royalty fees $ 26,060            
Exclusive World-wide License Agreement [Member]              
Intangible Assets [Line Items]              
Payment of license | €       € 10,000      
Royalty percentage       3.00%      
Amount owed under agreement           $ 0 $ 0